From the Journal: Biomicrofluidics
WASHINGTON, D.C., November 19, 2019 — Multiple myeloma is a type of blood cancer in which malignant plasma cells, a type of white blood cell, accumulate in the bone marrow. This leads to bone destruction and failure of the marrow, which in healthy individuals, produce all the body’s red blood cells. The most recent data from the American Cancer Society estimates that almost 27,000 new cases of MM are diagnosed every year, and of these, over 11,000 patients died.
Recent studies have shown some myeloma cells can leave the bone marrow and enter the blood stream. The presence of these cells, known as clonal circulating plasma cells, or cCPCs, in the blood has been correlated with shorter survival times.
Until now, it has been difficult to detect cCPCs in the blood. Existing methods cannot always detect the low levels of these cells in MM patients. In this week’s issue of Biomicrofluidics, from AIP Publishing, investigators report the development of a new device that can detect and isolate cCPCs from small samples of blood.
The device is a type of filter that separates malignant plasma cells from normal ones. It is based on a concept known as microfluidics. The filtering action is due to tiny pillars in the flow channel, designed in a precise way that allows normal blood cells through the filter while capturing the cancerous cCPCs.
The scientists who developed this device used a computational model to consider circular-, square- and diamond-shaped pillars of various sizes for their design. Their computer model showed the diamond shape provided a low resistance to flow. They also found by adjusting the diamond shape so that the pillars were longer and more pointed, the filtering action was improved.
Red blood cells are the smallest cells in blood plasma, with diameters in the range of 6-8 microns. White blood cells (WBCs) are bigger, with diameters ranging from 7 to 30 microns. While the cancerous cCPCs are large, with a size of 30-50 microns, the smallest cCPCs are about the same size as the largest WBCs. However, WBCs can deform and squeeze between the tiny pillars. The cCPCs are stiffer and cannot deform this way, so they end up stuck in the filter.
Studies were carried out with cultured cancer cells as well as on blood samples from patients with MM. The amount of cCPCs captured from patients with active MM was much higher than from patients in remission or from healthy individuals. Co-author Lidan You said, “This device shows great potential as a noninvasive method for either early detection or monitoring of MM disease progression.”
For more information:
Dongfang Ouyang, Yonghua Li, Wenqi He, Weicong Lin, Lina Hu, Chen Wang, Liangcheng Xu, Jaewon Park and Lidan You
University of Toronto, Southern University of Science and Technology, General Hospital of Southern Theater Command, Shenzhen People’s Hospital, Mount Sinai Hospital